AtaiBeckley Inc.

Listed Company

ATAICIK 0002081043NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$4.09M

Net Income

$-660.05M

Total Assets

$292.72M

Equity

$221.87M

Shares Out

368.17M

Op. Cash Flow

$-102.67M

ATAI$7.21+158.89% · past yearDBEQ Basic

Daily closing prices

Business

AtaiBeckley Inc. is a clinical-stage biotechnology company developing psychedelic-based and novel neuroplastogenic treatments for difficult-to-treat mental health disorders, particularly treatment-resistant depression and social anxiety disorder. The company's pipeline includes four core programs: BPL-003 (intranasal mebufotenin for TRD), VLS-01 (buccal DMT for TRD), EMP-01 (oral R-MDMA for social anxiety disorder), and a discovery program targeting non-hallucinogenic 5-HT2A receptor agonists for TRD and opioid use disorder. AtaiBeckley operates through a wholly-owned portfolio approach, conducting clinical trials across multiple geographies including the United States, United Kingdom, Canada, and Europe, with operations supported by scientific advisors and regulatory partnerships.

Summary from 10-K filed 2026-07-01

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Total revenues	4	308,000
Research and development	53	55
Acquisition of in-process research and development	530	0
General and administrative	65	48
Total operating expenses	648	103
Loss from operations	−644	−103
Interest income	1	778,000
Interest expense	−1	−3
Change in fair value of assets and liabilities, net	−24	−49
Gain on other investments	4	1
Gain on consolidation of Beckley Psytech	7	0
Change in fair value of digital assets, net	−1	0
Foreign exchange loss, net	2	−1
Other income (expense), net	−3	6
Other income (expense), net	−16	−46
Net loss before income taxes	−660	−148
Benefit from (provision for) income taxes	−298,000	356,000
Losses from investments in equity method investees, net of tax	0	−2
Net loss	−660	−150
Net loss attributable to noncontrolling interests	−100,000	−780,000
Net loss attributable to ATAI Life Sciences N.V. stockholders	−660	−149
Net loss per share attributable to AtaiBeckley Inc. shareholders - basic	−2.91	−0.93
Net loss per share attributable to AtaiBeckley Inc. shareholders - diluted	−2.91	−0.93
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - basic	227	160
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - diluted	227	160

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-02-28	FY 2024 2024-12-31
Cash and cash equivalents	85	—	18
Securities carried at fair value	135	—	45
Short-term restricted cash for other investments	0	—	10
Other current investments held at fair value	35	—	0
Prepaid expenses and other current assets	20	—	8
Total current assets	276	—	80
Property and equipment, net	2	—	3
Operating lease right-of-use assets, net	2	2	1
Other investments held at fair value	0	—	29
Other investments	0	—	42
Intangible assets, net	3	—	3
Goodwill	300,000	—	300,000
Digital assets	9	—	0
Other assets	1	—	850,000
Total assets	293	—	159
Accounts payable	5	—	3
Accrued liabilities	14	—	10
Current portion of lease liabilities	271,000	—	477,000
Short-term convertible promissory notes and derivative liability - related party	0	—	1
Short-term convertible promissory notes and derivative liability	0	—	2
Current portion of long-term debt	0	—	6
Deferred revenue	2	—	721,000
Other current liabilities	3	—	2
Total current liabilities	23	—	25
Contingent consideration liability - related party	104,000	—	110,000
Contingent consideration liabilities	205,000	—	212,000
Non-current portion of lease liabilities	2	—	732,000
Pre-funded warrant liabilities	44	—	0
Long-term debt, net	0	—	14
Other liabilities	754,000	—	3
Total liabilities	71	—	43
Commitments and contingencies (Note 20)	—	—	—
Preferred stock, $0.01 par value, 37,500,000 and zero shares authorized at December 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding at December 31, 2025 and December 31, 2024	0	—	0
Common stock, $0.01 par value at December 31, 2025 and 0.10 ($0.10) par value as of December 31, 2024; 750,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 363,280,522 and 167,959,752 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4	—	19
Additional paid-in capital	1,599	—	816
Accumulated other comprehensive loss	−21	—	−18
Accumulated deficit	−1,400	—	−700
Total stockholders' equity attributable to AtaiBeckley Inc. stockholders	222	—	116
Noncontrolling interests	127,000	—	257,000
Total stockholders' equity	222	—	117
Total liabilities and stockholders` equity	293	—	159

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation and amortization of long-term assets	1	473,000
Noncash lease expense	413,000	416,000
Amortization of debt discount	176,000	515,000
Stock-based compensation expense	14	25
Noncash change in the fair value of assets and liabilities, net	26	52
Acquisition of in-process research and development	530	0
Acquisition of in-process research and development	−7	0
Loss on disposal of fixed assets	692,000	0
Loss on lease termination	408,000	0
Loss on sale of investment held at fair value	0	2
Gain on dissolution of a variable interest entity	0	−1
Gain on settlement of pre-existing contract	0	−6
Impairment of intangible assets	33,000	919,000
Noncash change in the fair value of digital assets, net	1	0
Loss on extinguishment of debt	1	0
Unrealized foreign exchange (gain)	−2	1
Losses from investments in equity method investees, net of tax	0	2
Issuance costs allocated to pre-funded warrants	1	0
Noncash loss on sale of investment held at fair value	0	3
Other income, net	−182,000	−2
Prepaid expenses and other current assets	691,000	−1
Accounts payable	−2	−2
Accrued liabilities	−6	−7
Deferred revenue	766,000	721,000
Net cash used in operating activities	−103	−82
Proceeds from sale and maturities of securities carried at fair value	0	66
Proceeds from sale of other investment held at fair value	9	16
Cash received in acquisition of IntelGenx Corp.	0	359,000
Cash received in acquisition of Beckley Psytech Limited	5	0
Cash paid for securities carried at fair value	−89	0
Cash paid for investments	−10	−15
Cash paid for digital assets	−10	0
Cash paid for Psilera asset acquisition	−3	0
Cash paid for short-term convertible notes receivable and warrant - related party	0	−2
Cash paid for short-term notes receivable - related party	−10	−6
Cash paid for capitalized internal-use software development costs	0	−6,000
Cash paid for intangible asset	0	−83,000
Cash paid for property and equipment	−901,000	−6,000
Net cash provided by (used in) investing activities	−109	59
Proceeds from equity offerings, net of commissions	258	0
Proceeds from issuance of pre-funded warrants	22	0
Cash paid for common stock and pre-funded warrant issuance costs	−7	0
Proceeds from conversion of convertible notes to common shares	8	0
Proceeds from issuance of shares upon exercise of stock options	10	535,000
Proceeds from debt financing	0	5
Cash paid for debt financing costs	0	−161,000
Proceeds from other financing	148,000	0
Cash paid for debt extinguishment	−22	0
Net cash provided by financing activities	269	5
Effect of foreign exchange rate changes on cash	116,000	362,000
Net decrease in cash, cash equivalents and restricted cash	58	−18
Cash paid for interest	793,000	2
Cash paid for taxes	589,000	411,000
Right of use asset obtained in exchange for operating lease liabilities	2	0
Common stock issuance costs in accounts payable and accrued liabilities	6,000	0
Noncash exchange of convertible promissory note modification	0	4
Discharge of notes receivable	0	5
Noncash consideration for acquisition of Beckley Psytech	520	0
Noncash transaction costs for services rendered to Beckley Psytech	4	0
Noncash consideration for variable interest deconsolidation	0	115,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AtaiBeckley Inc.'s CIK number?

AtaiBeckley Inc.'s SEC CIK number is 0002081043 (2081043). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AtaiBeckley Inc.'s SEC filings?

All of AtaiBeckley Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AtaiBeckley Inc. last report earnings?

AtaiBeckley Inc. (ATAI) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-020708). This is AtaiBeckley Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AtaiBeckley Inc.'s most recent earnings 8-K?

AtaiBeckley Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001140361-26-020708. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AtaiBeckley Inc.'s latest earnings 8-K →
Look up any company's CIK number →